港股異動丨維生素概念股走高 兄弟科技發盈喜直線漲停
A股維生素概念股異動拉昇,其中,兄弟科技發盈喜,盤中直線拉昇封漲停,新和成漲近5%,聖達生物、浙江醫藥、華潤三九、新諾威、東北製藥跟漲。消息上,今年以來,維生素價格普遍回落,但尚未衝擊到廠商一季度業績。昨日晚間,新和成、兄弟科技兩家維生素廠商先後發佈一季度業績預告,盈利同比大幅增長,環比亦基本持平。據悉,本輪維生素行情從去年Q3開始啓動,很快見頂回落,今年以來主要維生素價格下行,加劇市場擔憂。值得注意的是,隨着時間推移,維生素廠商業績將不可避免受到產品價格回調影響。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.